The CRISPR companies are not OK

Taking stock of the drug industry, from the lab to the medicine chest

February 6, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Photo illustration: Christine Kao/STAT; Photos: Adobe STAT+ | The CRISPR companies are not OK Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR is hard to do profitably. By Jason Mast Remembering a remarkable Duchenne champion Leclaire, who died on Feb. 1, played a pivotal role in spurring the development of the first medicines to treat the condition. By Adam Feuerstein STAT+ | Personalized cancer vaccine shows potential in kidney cancer In the Phase 1 study, nine people with advanced kidney cancer became cancer-free after receiving personalized vaccines. By Elizabeth Cooney Molly Ferguson/STAT STAT+ | Previewing Immunovant's myasthenia gravis study readout — with all its quirky nuance In this edition of Adam's Biotech Scorecard, a look at upcoming results that will help determine whether batoclimab can compete against Argenx's Vyvgart.  By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser